首页 | 本学科首页   官方微博 | 高级检索  
     

生长抑素联合丹参治疗肝硬化并发上消化道出血与门静脉血栓形成的临床研究
引用本文:杨美荣,邓莉莉,刘斌,张国顺,杨立新,方正亚,孟冬梅. 生长抑素联合丹参治疗肝硬化并发上消化道出血与门静脉血栓形成的临床研究[J]. 中国现代医学杂志, 2017, 27(13): 63-66
作者姓名:杨美荣  邓莉莉  刘斌  张国顺  杨立新  方正亚  孟冬梅
作者单位:1.华北理工大学附属医院血液科,河北唐山063000;2.新疆巴州轮台县人民医院内一科,新疆轮台841600;3.华北理工大学附属医院消化内科,河北唐山063000;4.河北省唐山市传染病院肝病科,河北唐山063000
摘    要:
探讨生长抑素联合丹参对肝硬化并发上消化道出血(UGB)与门静脉血栓(PVT)形成的疗效作用。方法选取2010 年1 月-2016 年1 月在华北理工大学附属医院和唐山市传染病院住院的肝硬化并发UGB 与PVT形成的患者96 例。随机分为对照组24 例,给予对症支持治疗;生长抑素组24 例,给予对症支持治疗+ 生长抑素;丹参组24 例,给予对症支持治疗+ 丹参;联合治疗组24 例,给予对症支持治疗+ 生长抑素+ 丹参。观察4 组患者治疗后丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、胆碱酯酶(CHE)、肝功能Child评分、凝血酶原时间(PT)、纤维蛋白原(FIB)、血小板(PLT)、门静脉内径(PVD)的变化及临床症状改善情况。结果生长抑素组、丹参组、联合治疗组ALT、AST、CHE、肝功能Child评分、PT、FIB、PLT、PVD 与对照组相比,差异有统计学意义(p <0.05),以联合治疗组降低最为明显;联合治疗组与生长抑素组、丹参组比较,差异有统计学意义(p <0.05)。结论联合应用生长抑素和丹参治疗肝硬化并发上消化道出血与门静脉血栓形成有较好协同作用,疗效优于单纯西药治疗。

关 键 词:生长抑素;丹参;肝硬化;上消化道出血;门静脉血栓
收稿时间:2016-11-29

Clinical study of Somatostatin with Salviae in treatment of uppergastrointestinal bleeding and portal vein thrombosisin patients with liver cirrhosis
Mei-rong Yang,Li-li Deng,Bin Liu,Guo-shun Zhang,Li-xin Yang,Zheng-ya Fang,Dong-mei Meng. Clinical study of Somatostatin with Salviae in treatment of uppergastrointestinal bleeding and portal vein thrombosisin patients with liver cirrhosis[J]. China Journal of Modern Medicine, 2017, 27(13): 63-66
Authors:Mei-rong Yang  Li-li Deng  Bin Liu  Guo-shun Zhang  Li-xin Yang  Zheng-ya Fang  Dong-mei Meng
Affiliation:1. Department of Hematology, the Affiliated Hospital of North China University of Science andTechnology, Tangshan, Hebei 063000, China; 2. Department of Medicine, Luntai County People''sHospital, Luntai, Xinjiang 841600, China; 3. Department of Gastroenterology, the AffiliatedHospital of North China University of Science and Technology, Tangshan, Hebei 063000, China;4. Department of Hepatology, Tangshan City Hospital for Infectious Diseases,Tangshan, Hebei 063000, China
Abstract:
To investigate the therapeutic effect of Somatostatin with Salviae in treatment of upper gas-trointestinal bleeding and portal vein thrombosis in patients with liver cirrhosis. Methods Totally 96 patients with liver cirrhosis treated in the Affiliated Hospital of North China University of Science and Technology and Tangshan City Hospital for Infectious Diseases from January 2010 to January 2016 were enrolled. They were divided into four groups, namely control group (received symptomatic and supportive treatment), Somatostatin group (received symp-tomatic and supportive treatment and Somatostatin), Salviae group (given symptomatic and supportive treatment and Salviae), and combined treatment group (accepted symptomatic and supportive treatment, Somatostatin and Salviae) with 24 cases in each group. The changes of ALT, AST, CHE, liver function Child-Pugh classification, PT, FIB,PLT, PVD and prognosis were observed after treatment. Results ALT, AST, CHE, liver function Child-Pugh classifi-cation, PT, FIB, PLT and PVD in the Somatostatin, Salviae and combined treatment groups were significantly differ-ent from those in the control group (p < 0.05); the reduction was most obvious in the combined treatment group. The indexes of the combined treatment group were significantly different from those of the Somatostatin and Salviae groups (p < 0.05). Conclusions Combination of Somatostatin and Salviae has better synergistic therapeutic effect in the treatment of upper gastrointestinal bleeding and portal vein thrombosis in patients with liver cirrhosis, which is superior to using western medicine alone.
Keywords:Somatostatin   Salviae   liver cirrhosis   upper gastrointestinal bleeding   portal vein thrombosis
点击此处可从《中国现代医学杂志》浏览原始摘要信息
点击此处可从《中国现代医学杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号